Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02362997
Title Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

diffuse large B-cell lymphoma

Hodgkin's lymphoma

Therapies

Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.